AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.775
-0.255 (-3.63%)
As of 1:21PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.030
Open7.040
Bid6.760 x 3000
Ask6.770 x 3200
Day's Range6.710 - 7.080
52 Week Range5.250 - 33.630
Volume1,101,484
Avg. Volume3,063,237
Market Cap849.931M
Beta (3Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-1.479
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est9.00
Trade prices are not sourced from all markets
  • ACCESSWIRE5 hours ago

    Akorn to Press Buyout Lawsuit Further, Extensive Product Line, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Akorn, Inc. (AKRX), a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is involved in a lawsuit with Fresenius SE for canceling a $4.3 billion buyout of AKRX. AKRX specializes in generic pharmaceutical products in alternative dosage forms.

  • GlobeNewswire4 days ago

    Akorn Appeals Fresenius Kabi Ruling

    LAKE FOREST, Ill., Oct. 18, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that the company filed a notice of appeal to.

  • RM LAW Announces Investigation of Akorn, Inc.
    PR Newswire5 days ago

    RM LAW Announces Investigation of Akorn, Inc.

    BERWYN, Pa. , Oct. 17, 2018 /PRNewswire/ --  RM LAW, P.C. has commenced an investigation into potential securities law violations by certain officers of Akorn, Inc. ("Akorn" or the "Company") ...

  • Benzinga5 days ago

    Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential

    A closer look at Akorn, Inc. (NASDAQ: AKRX )'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock.  The Analyst Analyst David Amsellem upgraded Akorn from Neutral to Overweight ...

  • Financial Times6 days ago

    [$$] Fresenius: kidney punch

    Dialysis profits are out of control. So say Californian campaigners wanting to cap them. But making money from treating renal disease could be getting harder. Just ask German healthcare company Fresenius ...

  • Moody's6 days ago

    Akorn, Inc. -- Moody's downgrades Akorn to B3; outlook changed to developing

    Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to B3 from B1, the Probability of Default Rating to B3-PD from B1-PD and the senior secured term loan rating to B3 from B1. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-2 from SGL-1.

  • Implied Volatility Surging for Akorn (AKRX) Stock Options
    Zacks6 days ago

    Implied Volatility Surging for Akorn (AKRX) Stock Options

    Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wire11 days ago

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Akorn, Inc. breached their fiduciary duties to shareholders.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Akorn Inc NASDAQ/NGS:AKRX

  • Benzinga12 days ago

    Akorn's Generic Drug For Inadequate Eye Lashes Receives FDA Nod

    Akorn, Inc. (NASDAQ: AKRX ) shares  — which tumbled roughly 60 percent to $5.36 Oct. 1 on a ruling that Fresenius SE is free to exit its M&A agreement with Akorn —  had a reprieve early Wednesday. What ...

  • MarketWatch12 days ago

    Akorn's stock soars after FDA approves ANDA for hypotrichosis of eyelashes treatment

    Shares of Akorn Inc. ran up 13% in premarket trade Wednesday, putting them on track for a seventh-straight gain, after the generic drug maker said its new Abbreviated New Drug Application (ANDA) for Bimatoprost Ophthalmic Solution was approved by the Food and Drug Administration. Bimatoprost Ophthalmic Solution is indicated to treat hypotrichosis of the eyelashes. The stock had plummeted 59% on Oct. 1 to a 7 1/2-year closing low, after a court ruled in favor of Germany-based Fresenius SE & Co.'s attempt to end its buyout of Akorn. Since then, the stock has rallied 20.5% amid a six-session win streak through Tuesday. Despite the recent gains, the stock has tumbled 80% year to date through Tuesday, while the S&P 500 has advanced 7.7%.

  • GlobeNewswire12 days ago

    Akorn Receives Product Approval

    LAKE FOREST, Ill., Oct. 10, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has received a new Abbreviated New.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Why Akorn Stock Crashed Yesterday
    Market Realist20 days ago

    Why Akorn Stock Crashed Yesterday

    Akorn stock (AKRX) fell dramatically from $12.98 on September 28 to $5.36 on October 1 after the Delaware Court of Chancery ruled against the company and in favor of Fresenius. The ruling permits Fresenius to terminate the $4.8 billion merger agreement with Akorn. Fresenius has cited data integrity issues in regards to Akorn’s operations as one of the main reasons for the termination of the deal in its press release.

  • Why Infinera, Akorn, and Cal-Maine Foods Slumped Today
    Motley Fool21 days ago

    Why Infinera, Akorn, and Cal-Maine Foods Slumped Today

    Learn why these stocks missed the rally.

  • Akorn shares plummet after judge rules against Lake Forest drugmaker
    American City Business Journals21 days ago

    Akorn shares plummet after judge rules against Lake Forest drugmaker

    Lake Forest drug maker loses a court fight round in Delaware regarding a scotched merger deal; plans appeal.

  • Associated Press21 days ago

    GE, Tesla and GM jump while Akorn plunges

    Stocks that moved substantially or traded heavily Monday: General Electric Co., up 80 to $12.09 The industrial company replaced John Flannery, who became its CEO and chairman a little more than a year ...

  • Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal
    Bloomberg21 days ago

    Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal

    Fresenius SE had proper grounds for canceling a $4.3 billion buyout of rival drugmaker Akorn Inc. and doesn’t need to consummate the deal, a judge said in a ruling that comes as a blow to Akorn investors. ...

  • Reuters21 days ago

    Trade pact lifts European shares while Italy extends slide

    European shares rose on Monday as a new U.S.-Mexico-Canada trade pact lifted some of the gloom over global trade, while Italian stocks extended Friday's slide as top EU officials weighed in on the government's budget plans. There was no shortage of corporate news to drive the markets either, with Ryanair taking a 12.5 percent dive after a profit warning, Fresenius boosted by a ruling in its favour, and Linde rising on a regulator's green light for its merger with Praxair. "News overnight of a late agreement between the U.S. and Canada to salvage the NAFTA trade agreement should give a boost to global risk appetite at the start of the fourth quarter," wrote Peel Hunt strategist Ian Williams, adding the deal "may offer encouragement that the other global trade disputes can be settled satisfactorily".

  • Reuters21 days ago

    Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

    Germany's Fresenius SE (FREG.DE) won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc (AKRX.O), sparking a more than 50 percent fall in the U.S. generic drugmaker's shares. Travis Laster, a judge on the Delaware Court of Chancery, ruled that Fresenius had validly terminated its merger agreement following a dramatic decline in Akorn's business. In a surprise ruling as Delaware judges have generally held buyers to merger deals, Laster rejected Akorn's argument that Fresenius Chief Executive Stephan Sturm suffered buyer's remorse and directed his lawyers to construct a case to end the deal.

  • Here's Why Akorn Inc. Collapsed Today
    Motley Fool21 days ago

    Here's Why Akorn Inc. Collapsed Today

    It's official: A judge ruled that Fresenius can abandon the previously announced acquisition of Akorn.

  • MarketWatch21 days ago

    Akorn stock set to drop nearly 50% after court supports Fresenius ending $4.3 bln merger

    Akorn Inc. shares dropped about 47% in Monday premarket trade after a Delaware court ruled in favor of Fresenius SE & Co. , which has sought to end a $4.3 billion merger. Akorn shares have been halted, while Fresenius shares rose 8.5% in heavy Monday morning trade. The Germany-based Fresenius previously terminated the merger "due to Akorn's failure to fulfill several closing conditions," the company said in a Monday statement. "An independent investigation initiated by Fresenius had revealed, among other things, material breaches of FDA data integrity requirements relating to Akorn's operations." The merger had been agreed to in April 2017, and Fresenius said earlier this year that it was ending it. Akorn subsequently sued in late April. The Lake Forest, IL-based generic drugmaker said that it was disappointed by the court's decision and plans to appeal. Akorn shares have dropped nearly 22% over the last three months, and Fresenius shares have slumped 0.2%. The S&P 500 has risen 7.8% in the same time, and the Dow Jones Industrial Average has risen 9.7%.

  • Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal
    Bloomberg Video21 days ago

    Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal

    Oct.01 -- Fresenius SE had proper grounds for canceling a $4.3 billion buyout of rival drugmaker Akorn Inc. and doesn’t need to consummate the deal, a judge said in a ruling that comes as a blow to Akorn investors. Bloomberg's Ed Hammond has more on "Bloomberg Markets: The Close."

  • Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal
    Bloomberg21 days ago

    Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal

    Oct.01 -- Fresenius SE had proper grounds for canceling a $4.3 billion buyout of rival drugmaker Akorn Inc. and doesn’t need to consummate the deal, a judge said in a ruling that comes as a blow to Akorn investors. Bloomberg's Ed Hammond has more on "Bloomberg Markets: The Close."